Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Phase 2
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Nasopharyngeal Cancer
Both
Nasopharyngeal Cancer
Trial Information
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Inclusion Criteria:
- histologically confirmed nasopharyngeal cancer
- chemotherapy or radiotherapy naive (but, including patients completed 6 months before
the enrollment)
- ECOG 0-1
- at least one measurable lesion
Exclusion Criteria:
- other cancer
- pregnat
- docetaxel hypersentitivity history
- severe heart or pulmonary disease
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
objective response rate
Outcome Time Frame:
6 months after the enrollment of the last patients
Safety Issue:
No
Authority:
South Korea: Korea Food and Drug Administration (KFDA)
Study ID:
2006-07-005
NCT ID:
NCT01312311
Start Date:
July 2006
Completion Date:
Related Keywords:
- Nasopharyngeal Cancer
- nasopharyngeal cancer
- weekly docetaxel
- cisplatin
- Nasopharyngeal Neoplasms
Name | Location |
|---|
